Difference between revisions of "Bleomycin (Blenoxane)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
Warner-admin (talk | contribs) m (Text replacement - "Basal cell carcinoma (BCC)" to "Cutaneous basal cell carcinoma") |
||
| Line 9: | Line 9: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Adenocarcinoma of unknown primary]] | *[[Adenocarcinoma of unknown primary]] | ||
| − | *[[ | + | *[[Cutaneous basal cell carcinoma]] |
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| Line 46: | Line 46: | ||
[[Category:Adenocarcinoma of unknown primary medications]] | [[Category:Adenocarcinoma of unknown primary medications]] | ||
| − | [[Category: | + | [[Category:Cutaneous basal cell carcinoma medications]] |
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
Revision as of 19:22, 16 August 2018
General information
Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.[1]
Route: IV, IM, SC, intrapleural
Extravasation: irritant or neutral, depending on reference
- 1 unit of bleomycin = 1 mg of bleomycin
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adenocarcinoma of unknown primary
- Cutaneous basal cell carcinoma
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Osteosarcoma
- Penile cancer
- Post-transplant lymphoproliferative disorder
- Squamous cell carcinoma (SCC)
- Testicular cancer
- Vascular sarcoma
Patient drug information
- Bleomycin (Blenoxane) patient drug information (Chemocare)[2]
- Bleomycin (Blenoxane) patient drug information (UpToDate)[3]
History of changes in FDA indication
- 7/31/1973: Initial FDA approval
Also known as
- Brand names: Blenoxane, Bleo, Bleocin, Bleocip, Bleopar, Bleowel
References
- Drugs
- Intracavitary medications
- Intramuscular medications
- Intravenous medications
- Subcutaneous medications
- Irritant chemotherapy
- Neutral chemotherapy
- DNA synthesis inhibitors
- Adenocarcinoma of unknown primary medications
- Cutaneous basal cell carcinoma medications
- Diffuse large B-cell lymphoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Osteosarcoma medications
- Penile cancer medications
- Post-transplant lymphoproliferative disorder medications
- Squamous cell carcinoma (SCC) medications
- Testicular cancer medications
- Vascular sarcoma medications
- FDA approved in 1973
- WHO Essential Cancer Medicine